This article is more than 5 years old. Information may no longer be current.
Factor V Leiden and prothrombin mutation linked to venous thrombosis
The occurrence of Factor V Leiden and prothrombin mutation could be linked to central venous catheter-related thrombosis in patients with cancer, according to new data.
Researchers in Italy performed a meta-analysis of 10 studies that were conducted to measure the incidence of prethrombotic abnormalities among patients with cancer who had central venous catheter-related thrombotic events compared with patients with cancer who did not have thrombosis. The 10 studies included 1,000 patients.
The combined OR for central venous catheter-related thrombosis was 4.6 (95% CI, 2.6-8.1) for patients with Factor V Leiden. Patients with prothrombin mutation had a combined OR of 4.9 (95% CI, 1.7-14.3) for central venous catheter-related thrombosis.
Catheter-related thrombosis attributable risk was estimated at 4.5% for prothrombin mutation and 13.1% for Factor V Leiden. – by Paul Burress
J Thromb Haemost. 2008;6:70-75.
The very significant, approximate 10% rate of catheter thromboses suggests assay of cancer patients for prothrombin and Factor V mutations might be worthwhile. Optimal prophylactic anticoagulation would seem rational and important in catheterized cancer patients with genetic thrombophilia.
– Harry S. Jacob, MD
HemOnc Today Chief Medical Editor